Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
Beatriz Grinsztejn,Mina C. Hosseinipour,Heather J. Ribaudo,Susan Swindells,Joseph J. Eron,Ying Q. Chen,Lei Wang,San San Ou,Maija Anderson,Marybeth McCauley,Theresa Gamble,N. Kumarasamy,James Hakim,Johnstone Kumwenda,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Marineide Gonçalves de Melo,Kenneth H. Mayer,Susan H. Eshleman,Estelle Piwowar-Manning,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Ian Sanne,Joel E. Gallant,Irving F. Hoffman,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Diane V. Havlir,Myron S. Cohen +32 more
Reads0
Chats0
TLDR
The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.Abstract:
Summary Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. H owever, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the eff ects of early and delayed initiation of antiretroviral treatment on clinical outcomes. Methods The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratifi ed by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581. Findings 1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group (two individuals were excluded from this group af ter randomisation). Median CD4 counts at randomisation were 442 (IQR 373–522) cells per μL in patients assigned to the early treatment group and 428 (357–522) cells per μL in those allocated delayed antiretroviral treatment. In the delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197–249) cells per μL. Primary clinical events were reported in 57 individuals assigned to early treatment initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0·73, 95% CI 0·52–1·03; p=0·074). New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43–0·96; p=0·031), tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28–0·89, p=0·018), and primary nonAIDS events were rare (12 in the early group vs nine with delayed treatment). In total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24·9 per 100 person-years, 95% CI 22·5–27·5) versus 585 in the delayed treatment group (29·2 per 100 person-years, 26·5–32·1; p=0·025). 26 people died, 11 who were allocated to early antiretroviral treatment and 15 who were assigned to the delayed treatment group.read more
Citations
More filters
Journal ArticleDOI
Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test.
Hsin-Yun Sun,Po-Ren Hsueh,Wen-Chun Liu,Yi-Ching Su,Sui-Yuan Chang,Chien-Ching Hung,Shan-Chwen Chang +6 more
TL;DR: The risk of developing active TB in HIV-infected patients with positive T-Spot.TB receiving combination antiretroviral therapy is low in Taiwan where the national TB program has led to a sustained decrease in TB incidence.
Journal ArticleDOI
Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Shweta Sharma,Abdel Babiker,Sean Emery,Fred M. Gordin,Jens D Lundgren,J. N. Neaton,E. Bakowska,Mauro Schechter,M. J. Wiselka,Marcelo Wolff +9 more
TL;DR: The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV‐positive individuals with CD4 cell counts above 500 cells/μL.
Journal ArticleDOI
HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.
Bluma G. Brenner,Ruxandra-Ilinca Ibanescu,Maureen Oliveira,Michel Roger,Isabelle Hardy,Jean-Pierre Routy,Fred Kyeyune,Miguel E. Quiñones-Mateu,Miguel E. Quiñones-Mateu,Mark A. Wainberg +9 more
TL;DR: Large cluster HIV-1 isolates selected for resistance to dolutegravir, elvitegravIR and lamivudine faster than HIV- 1 strains forming small clusters, suggesting virological features of large cluster viruses that may favour their transmissibility, replicative competence and potential to escape selective antiretroviral drug pressure are needed.
Journal ArticleDOI
Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence
Wim Delva,St�phane Helleringer +1 more
TL;DR: Delva et al. as mentioned in this paper found that clusters of antiretroviral treatment (ART) users in sexual networks can modify the impact of ART on HIV incidence, which is beyond risk compensation.
Journal ArticleDOI
African potato (Hypoxis hemerocallidea): a systematic review of its chemistry, pharmacology and ethno medicinal properties.
TL;DR: Results showed that the tuberous rootstock (corm) of African Potato is used traditionally to treat wasting diseases, testicular tumours, insanity, barrenness, impotency, bad dreams, intestinal parasites, urinary infection, cardiac disease and enhancing immunity.
References
More filters
Journal ArticleDOI
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
TL;DR: In this article, Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples.
Journal ArticleDOI
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
Anthony S. Fauci,John G. Bartlett,Eric P. Goosby,M. D. Smith,H. J. Kaiser,S. W. Chang,James M. Anderson,R. Armstead,A. C. Baker,David A Barr,Samuel A. Bozzette,S. Cox,M. Delaney,Fred M. Gordin,W. Greaves,M. Harrington,J. J. Henning,Martin S. Hirsch,J. Jacobs,Richard Marlink,C. Maxwell,J. W. Mellors,D. B. Nash,S. Perryman,Robert T. Schooley,R. Sherer,Stephen A. Spector,G. Torres,Paul A. Volberding,B. A. Brady,E. M. Daniels,D. Feigal,Mark B. Feinberg,H. D. Gayle,T. R. Graydon,Jonathan E. Kaplan,Abe M. Macher,R. F. Martin,Henry Masur,Lynne M. Mofenson,J. Murray,J. O'Neill,L. C. Perez,R. Riseberg,S. Shekar,Sharilyn K. Stanley,J. Whitescarver +46 more
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.
Journal ArticleDOI
Prevention of HIV-1 infection with early antiretroviral therapy
TL;DR: The exciting evidence generated by this paper – that antiretroviral treatment of HIV-1 infection definitively reduces the risk of onward transmission of the virus by 96% – was rightly dubbed Science magazine's ‘Breakthrough of the Year’ in 2011.
Journal ArticleDOI
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard,Judith A. Aberg,Joseph J. Eron,Jennifer F Hoy,Amalio Telenti,Constance A. Benson,David M. Burger,Pedro Cahn,Joel E. Gallant,Marshall J. Glesby,Peter Reiss,Michael S. Saag,David L. Thomas,Donna M. Jacobsen,Paul A. Volberding +14 more
TL;DR: This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Journal ArticleDOI
Overadjustment bias and unnecessary adjustment in epidemiologic studies.
TL;DR: This work uses causal diagrams and an empirical example (the effect of maternal smoking on neonatal mortality) to illustrate and clarify the definition of overadjustment bias, and to distinguish over adjustment bias from unnecessary adjustment.
Related Papers (5)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more